These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 4797270)

  • 1. Quantitation of plasma fibrinogen in the presence of fibrinogen degradation products.
    Arnesen H
    Scand J Haematol; 1973; 11(3):204-9. PubMed ID: 4797270
    [No Abstract]   [Full Text] [Related]  

  • 2. The influence of fibrinogen degradation products on the reptilase-time of plasma.
    Arnesen H; Kierulf P; Godal HC
    Scand J Haematol; 1973; 11(5):360-6. PubMed ID: 4798341
    [No Abstract]   [Full Text] [Related]  

  • 3. Studies on the thrombin clotting time. I. The influence of fibrinogen degradation products.
    Arnesen H; Godal HC
    Scand J Haematol; 1973; 10(3):232-40. PubMed ID: 4797626
    [No Abstract]   [Full Text] [Related]  

  • 4. The tanned red cell hemagglutination-inhibition immunoassay of fibrinogen-fibrin degradation products. Methodological and statistical aspects.
    Hahn L
    Thromb Res; 1974 Mar; 4(3):417-36. PubMed ID: 4857332
    [No Abstract]   [Full Text] [Related]  

  • 5. [Assay methods and significance of fibrin-fibrinogen degradation products in blood].
    Shinada S
    Nihon Ketsueki Gakkai Zasshi; 1972 Oct; 35(5):607-16. PubMed ID: 4677376
    [No Abstract]   [Full Text] [Related]  

  • 6. Assessment of fibrin degradation products during fibrinolytic therapy for acute myocardial infarction.
    Francis CW; Connaghan DG; Marder VJ
    Circulation; 1986 Nov; 74(5):1027-36. PubMed ID: 3533310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Release of fibrinopeptides from fibrinolytic fibrinogen fragment E.
    Peyer A; Straub PW
    Thromb Diath Haemorrh; 1973 May; 29(2):300-12. PubMed ID: 4271587
    [No Abstract]   [Full Text] [Related]  

  • 8. Degradation of plasmin-resistant fibrinogen-fibrin breakdown products in rheumatoid synovial fluid by Brinastrase.
    Andersen RB; Gormsen J
    Scand J Rheumatol; 1973; 2(2):81-6. PubMed ID: 4270793
    [No Abstract]   [Full Text] [Related]  

  • 9. Urinary fibrin-fibrinogen degradation products (FDP) in renal diseases and during thrombolytic therapy.
    Hedner U
    Scand J Clin Lab Invest; 1973 Oct; 32(2):175-82. PubMed ID: 4588514
    [No Abstract]   [Full Text] [Related]  

  • 10. Fibrinogen Cleveland II. An abnormal fibrinogen with defective release of fibrinopeptide A.
    Crum ED; Shainoff JR; Graham RC; Ratnoff OD
    J Clin Invest; 1974 May; 53(5):1308-19. PubMed ID: 4856883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical evaluation of low dose of urokinase in acute myocardial infarction. A double-blind study.
    Gormsen J; Tidstrom B; Feddersen C; Ploug J
    Acta Med Scand; 1973; 194(3):191-8. PubMed ID: 4583532
    [No Abstract]   [Full Text] [Related]  

  • 12. Studies on the thrombin clotting time. II. The influence of fibrin degradation products.
    Arnesen H
    Scand J Haematol; 1973; 10(4):291-7. PubMed ID: 4764611
    [No Abstract]   [Full Text] [Related]  

  • 13. [Antisera to fibrinogen degradation products, fragments D and E].
    Sudo T; Fujisawa M; Okumura H; Manita H
    Nihon Ketsueki Gakkai Zasshi; 1972 Oct; 35(5):652-3. PubMed ID: 4269798
    [No Abstract]   [Full Text] [Related]  

  • 14. A facile separation of fragments D and E from the fibrinogen-fibrin degradation products of three mammalian species.
    Chen JP; Shurley HM; Vickroy M
    Biochem Biophys Res Commun; 1974 Nov; 61(1):66-71. PubMed ID: 4280310
    [No Abstract]   [Full Text] [Related]  

  • 15. Characterization and significance of urinary fibrin degradation products.
    Cortes P; Potter EV; Kwaan HC
    J Lab Clin Med; 1973 Sep; 82(3):377-89. PubMed ID: 4199524
    [No Abstract]   [Full Text] [Related]  

  • 16. Detection of fibrinogen-fibrin degradation products by counterelectrophoresis.
    Brody JI
    J Clin Pathol; 1972 Sep; 25(9):754-6. PubMed ID: 5086217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complex formation between fibrinogen, fibrinogen degradation products and insolubilized fibrin monomer at various pH values.
    Matthias FR
    Haemostasis; 1973-1974; 2(6):277-80. PubMed ID: 4802436
    [No Abstract]   [Full Text] [Related]  

  • 18. Mechanisms for elevated fibrin/fibrinogen degradation products in acute experimental pulmonary embolism.
    Cade J; Hirsh J; Regoeczi E
    Blood; 1975 Apr; 45(4):563-8. PubMed ID: 1115842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fibrinogen and fibrin degradation products].
    Fujimaki M; Ikematsu S; Kato M
    Rinsho Byori; 1973 Jan; 21(1):31-6. PubMed ID: 4267650
    [No Abstract]   [Full Text] [Related]  

  • 20. Fibrinogen degradation products and fibrinogen to fibrin conversion.
    Arnesen H
    Scand J Haematol Suppl; 1971; 13():245-52. PubMed ID: 5290685
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.